Jidapa Suwannachat
Research Subjects
Jidapa Suwannachat has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ananyalak Yoisara
Wichianburi Hospital, Wichianburi, Phetchabun 67130, Thailand
1 shared publication - Anchalee Karagate
Khao Kho Hospital, Khao Kho, Phetchabun 67270, Thailand
1 shared publication - Duong Hoang Huy Le
Biomedical Research and Diagnostics Center,Pham Ngoc Thach University of Medicine,Ho Chi Minh City,Vietnam; Medical Biochemistry and Molecular Biology Department, Faculty of Fundamental Sciences and Basic Medical Sciences,Pham Ngoc Thach University of Medicine,Ho Chi Minh City,Vietnam, Vietnam
1 shared publication - Jarunlak Saokeaw
Nam Nao Hospital, Nam Nao District, Phetchabun 67260, Thailand
1 shared publication - Jiratchaya Puenpa
Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
1 shared publication - Kawin Thongnoi
Buengsamphan Hospital, Buengsamphan, Phetchabun 67160, Thailand
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (8) , 215
Achieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model
The World Health Organization targets hepatitis C virus (HCV) elimination as a public-health threat by 2030. Phetchabun province, in lower northern Thailand, has historically reported one of the country’s highest HCV seroprevalence rates. We describe a province-wide, decentralized test-to-treat micro-elimination program implemented within Thailand’s universal health-coverage system. Adults aged 35–64 years (2020–2024) and individuals born before 1992 (late 2023) across all 11 districts were screened using fingerstick anti-HCV rapid diagnostic tests at sub-district health-promoting hospitals. Reactive participants underwent confirmatory HCV-RNA testing at three regional nodes. Eligible patients received pangenotypic sofosbuvir/velpatasvir for 12 weeks, with ribavirin added for cirrhosis. Sustained virological response at 12 weeks post-treatment (SVR12) was the primary outcome. Of 400,567 targeted individuals, 389,547 (97.3%) were screened; 18,340 (4.71%) were anti-HCV reactive. Confirmatory HCV-RNA testing was completed in 14,845 (80.9%), of whom 10,996 (74.1%) had active infection. Of 8961 treatment-eligible patients, 8842 (98.7%) received DAA therapy. Among 6719 evaluable for SVR12, 6474 (96.4%) achieved cure. This simplified, domestically financed, decentralized test-to-treat model achieved WHO-target-level diagnosis, treatment, and cure rates at provincial scale, offering a scalable framework for HCV micro-elimination in low- and middle-income countries.
- 1 August 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (8) , 215
Open AccessAchieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model
The World Health Organization targets hepatitis C virus (HCV) elimination as a public-health threat by 2030. Phetchabun province, in lower northern Thailand, has historically reported one of the country’s highest HCV seroprevalence rates. We describe a province-wide, decentralized test-to-treat micro-elimination program implemented within Thailand’s universal health-coverage system. Adults aged 35–64 years (2020–2024) and individuals born before 1992 (late 2023) across all 11 districts were screened using fingerstick anti-HCV rapid diagnostic tests at sub-district health-promoting hospitals. Reactive participants underwent confirmatory HCV-RNA testing at three regional nodes. Eligible patients received pangenotypic sofosbuvir/velpatasvir for 12 weeks, with ribavirin added for cirrhosis. Sustained virological response at 12 weeks post-treatment (SVR12) was the primary outcome. Of 400,567 targeted individuals, 389,547 (97.3%) were screened; 18,340 (4.71%) were anti-HCV reactive. Confirmatory HCV-RNA testing was completed in 14,845 (80.9%), of whom 10,996 (74.1%) had active infection. Of 8961 treatment-eligible patients, 8842 (98.7%) received DAA therapy. Among 6719 evaluable for SVR12, 6474 (96.4%) achieved cure. This simplified, domestically financed, decentralized test-to-treat model achieved WHO-target-level diagnosis, treatment, and cure rates at provincial scale, offering a scalable framework for HCV micro-elimination in low- and middle-income countries.